STTK - Earnings call 3 2023 | Shattuck Labs, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

I will now turn the call over to your host, Conor Richardson, Vice President of Investor Relations at Shattuck Labs. Connor, please go ahead.

Conor Richardson

Thank you, operator. welcome quarter Shattuck recent XXXX and regarding Conference business everyone, third our financial morning, to Labs the Call updates. Good results and

premarket be release morning website, Relations shattucklabs.com. press reporting financial our was The our section of and on found issued can the Investor results this

During call, clinical including development leadership the team business provide a -- this of XXXX the and morning's overview third Shattuck will quarter of updates.

Chief Dr. Medical be our Dr. Chief Officer Taylor today's Schreiber, our on Co-Founder our and Mr. call will Pandite; Speaking Officer, Andrew Officer, and Lini Executive Financial Scientific Chief Neill.

open for We the will remarks. prepared following then call questions our

Reform I Before of represent statements judgment meaning begin, actual webcast safe uncertainties XXXX. contains as remind statements management's and differ may cause in could of would and we these results Litigation or you from risks of that to the today's involve materially statements. Act like implied to expressed by that of certain harbor Such the within provisions today forward-looking Securities those Private

more and website are corporate recent statements these the ended shattucklabs.com. other which refer with XXXX. XX, XX-Q the Form from our XXXX, represent please risks our as the September for filings uncertainties, on report November on views most and X, quarterly SEC, our or our forward-looking to on today, available SEC's For information website, quarter Any of

turn will call to our over now I the Taylor? With Executive that, Officer. Dr. Schreiber, Chief

Taylor Schreiber

thank morning, you today. and joining Good Conor. everyone, you, Thank for us

and data from able to begin clinical We clinical our product we a hematologic are stage advanced SL-XXXXXX stage candidate, pleased where solid to very has are lead programs. that sharing tumor both our

trial clinical forward first details Phase acute to efficacy myeloid or look pleased call. and clinical across throughout myelodysplastic in Ia/b and ovarian high-risk to leukemia also are cancer Ib platinum-resistant providing trials, clinical data We the Phase responses our including we syndromes. observed in our have our our trial Importantly, more

as XXX trial SL-XXXXXX in platinum-resistant from -- morning, refer pegylated the clinical we doxorubicin with This ovarian interim of combination For the XXX. call, we of -- will in will with to cancer. Ib rest data Phase patients liposomal discuss and our

In higher-risk Meeting myeloid that data in last our syndromes clinical in from was December. the or Society an acute be Annual leukemia trial American Ia/b week will we early in myelodysplastic abstract presented addition, described ongoing will discuss of and at the encouraging Hematology released Phase

include MDS primarily dose in data higher-risk as and data and relapsed/refractory combination These escalation XXX with patients. for monotherapy AML in azacitidine

immune receptor engagement. is dual-sided protein. directly also XXX activates by reminder, and CDXX a a cells fusion CDXX checkpoint As inhibits It the

over Phase or year PROC other from cancer other ovarian this escalation data the Earlier in platinum-resistant we Ia anemia. in have these shared encountered The has months. safety believe, CDXX that safety not at cytopenias to ASCO, have trial significantly regarding clinical pathway. the toxicity, led agents individual specific drawn landscape currently evolved be in Several to are of not Fc advanced of These receptors conclusions the XXX engage regarding being the CDXX including with avoid gamma targeted result the pathway CDXX challenges skepticism the to a confined We anemias potential agents. the We related itself. that however, of destructive target should believe clinical as have challenges and only the utility designed past issues and to and significant design are issues We inherent to CDXX XX that CDXX the significant class. clinical our programs patients. some plagued clinical dose order agents

to differentiates to tolerability other in XXX This [indiscernible] domain. a dose in response improved to profile does accelerated profile led rates, of responses XXX date. XXX destructive durability that through response of may anemia, pharmacodynamic our safety also demonstrated from true differentiated contribute and remains observation and data already encouraged not by agonist the has cause this of today. CDXX kinetics remain XXX all and attribute That of We CDXX inhibitors and escalation its studies

a will Lini our results our high XXX level, the Dr. [indiscernible] at in call Medical by PLD pegylated with in PROC. interim doxorubicin, confidence patients -- we Pande, is bolstered Chief of Officer, liposomal combination expand with will which

As of in AML. exceed response Phase and if highlight we refractory October clinical and relapsed recent XX, response MDS and -- monotherapy of evaluating also monotherapy have trial holds, high-risk XXX both observed XX%, the benchmark overall sponsored an of combination JAVELIN patients trial. Ovarian data it in with our rate would as PLD with X% XXX, XXXX, Ia/b which Lini rate in Pfizer will from the azacitidine

XXXX the be completed of dose in the ASH quarter at will Annual these in and and December. second study data escalation We portion presented Meeting the -- this upcoming of

We have different with expansion patients TPXX azacitidine in high-risk cohorts previously or where combined X with is initiated mutant AML. frontline dose XXX being MDS untreated

this attribute of We very in frontline month. we has cohorts expansion in and which profile the investigators' pleased ASH these proceeded the XXX. trial for very need and are high to forward We dose an to regarding sharing from patients enrollment quickly, update the differentiated the momentum conjunction unmet look our with next with enthusiasm interim

update who will an I activities. and and our into recent programs call that, now data to will turn dive With over the on clinical clinical provide Lini,

Arundathy Pandite

be that our XXXX Thanks, progress. for Taylor, patients . grateful themselves have operational a morning, this participating continues importantly, the to our I'm most and team, and focused of investigators execution. efforts year everyone. enabled relentless the good of

PLD with Phase AML patients Taylor I the will some trial a/b in color abstract As last in week's first provide MDS. on cancer. with combination ovarian from combination our XXX patients and our an investigating then update and I data in Phase higher-risk investigating ASH trial provide outlined, platinum-resistant Ib with in azacitidine from XXX in with

in Phase combination XXX cancer. platinum-resistant Ib with ongoing our with trial clinical start ovarian Let's of patients

into cutoff As patients data with study. XX, been cancer platinum-resistant date this of of have the October XX XXXX, ovarian enrolled

profile, with the the X.X lines prior of PLD an profile of of median which systemic acceptable plus consistent a XXX individual agents. have patients was therapy. safety These safety had

For adverse event was XXX, common the most grade reaction, mostly X X. drug-related infusion-related or

for October partial response XXXX, responses, X patients XX efficacy. of the and partial evaluable X responses. were XX, of data unconfirmed confirmed X partial observed cutoff As We date

November date of response reached XXXX, and both have confirmatory not stable disease response partial assessment. X of of best had the are study with X, patients on a unconfirmed responses patients patients still As Four and progressive disease. had

XXXX, included trial PLD disease a enrolled trial, a recently patients Ovarian As this which data the of of October XXX in the in sponsored cutoff are arm. to of trial the date JAVELIN similar characteristics XX, patients control is the of Pfizer the enrolled the that published randomized characteristics

response JAVELIN monotherapy with the overall for treated rate the In patients PLD trial, was X%.

X date, in patients with cm of Additionally, proportion A disease higher which in poor prognostic are enrolled bulky diameter bevacizumab, trials have factors. pretreatment and to both measuring of over our

and the to We expect additional data quarter midyear this response cohort expansion response end durability from and provide XXXX. of by full the cohorts

I more by and and -- the cohort updates patients longer look this to Overall, follow-up. are we encouraged with from forward emerging data combination

XXXX. expect combination are in dosing cancer. data also XXX enrollment Enrollment from trial Phase soravtansine, midyear report in initial platinum-resistant quickly, continuing progressing mirvetuximab We our and combination we to in Ib are of with this ovarian trial

activity are I AML with of monotherapy pharmacokinetics I our trial MDS. standard current -- the and clinical have made antitumor pharmacodynamic us Phase both to XXX a/b progress evaluating of trial, in in safety high-risk azacitidine care. In Let as the tolerability in and now we effects and we turn this combination

therapy. azacitidine. of cutoff combination XX As as with are XXXX. XX cohort described XX, There adult data May relapsed/refractory monotherapy in primarily X date our in in of XXX and abstract have received of or patients the or a combination as with of had the patients AML These in ASH patients median high-risk cohort lines XX MDS prior the monotherapy patients

In safety profile in this a acceptable combination. trial, XXX monotherapy had as and an

X. a the state a For XXX, drug-related targeted subsequently relapsed/refractory reported mostly a allogeneic Monotherapy and patient TPXX by CDXX common reaction, response grade infusion-related heavily remains event were responses in relapsed/refractory and not to with we was to was a patient. XXX taken agents pretreated adverse mutant pretreated free. been monotherapy AML patients. particularly encouraged or This have AML achieved most in Consequently, leukemia-free heavily X morphologic leukemia response monotherapy, had transplant rapid

activity observed Additionally, the reduction. in patients, we form in of antileukemic blast count other also

patients in the included several We mutant dose untreated enrolled previously are trial. abstract. TPXX MDS the escalation in portion high-risk also ASH data of These our

high-risk disease, had whom marrow-complete and study high-risk on As has with combination MDS. data complete XXXX, a July mutant best bone of marrow patient cutoff X, observed azacitidine We in treatment-related mutan in of stable a to response TPXX evaluable in of to X patient who response taken the was was X transplant. remains date X in who transplant. Two previously patients MDS taken risk X response antitumor TPXX untreated observed of patients with X activity

mechanism Overall, of action growing its patients unmet encouraged data body of XXX higher-risk the the of unique of and MDS. to and with we needs therapeutic address are by AML potential validates that the

and Our both data driven marrow. evidence blood to continue bone CDXX peripheral show pharmacodynamic in of activity,

both ASH durability company-sponsored and the system next terms may improved CDXX and the is the indications in during refractory rate data of dose frontline and We believe event immune involvement sharing and important of blockade to of response activation ASH CDXX complete at adaptive to of the relapsed forward We that of meeting the month. the in resulting look the cohort from response. time [indiscernible] patients data around portion provide the presenting improvement a of escalation trial initial expansion significant

over discuss update. will turn now that, With I the . to Andrew? Neill our Mr. financial to call

Andrew Neill

Lini, you, Thank good and everyone. morning,

financial earnings the to a this XXXX would our quarter As I call, disclosures. release in of morning. key the premarket filed are at available results outset third and XX-Q full our Conor on mentioned focus few for the like the from press points of

to continue be positioned well financially. We

XXXX, quarter million XXXX, As In development cash investments our and million. of expenses $XX.X the $XXX.X quarter were were third quarter cash of million XXXX, million compared and In to third research of $X.X XX, expenses $XX.X -- administrative and our the were as compared quarter XXXX. and September to XXXX. equivalents and $X.X general -- for as of the million the our third for The third of

Our million, million diluted $XX.X to third loss or for of net $X.XX per net of or $X.XX third loss $XX.X basic XXXX of and was diluted the and quarter a the as per XXXX. for share quarter share compared basic

financial business current clinical with that that proceeds trials runway from and/or development may received may plans company's fund excludes operational current and our XXXX. development operating year-end reiterate I beyond its investments on will cash believes results be Based sufficient -- operations cash Phase associated equivalents our be transactions activities cash based plans, Shattuck is any clinical and and of and our we be on additional guidance we its SL-XXXXXX. -- guidance. We development through from any This its capital to costs undertaken.

I'll that, the With Dr. comments. Taylor? for to back final hand call Schreiber

Taylor Schreiber

third trials. and progress Andrew. made of you, X we cohorts expansion In higher-risk Thank quarter different PROC, the in MDS XXXX, ongoing excellent AML across our the

We several end and updates through this the of milestones year. additional clinical expect

For we relapsed in Phase refractory complete and to data ASH updates, present trial XXth clinical at dose data from escalation XXX the patients Annual expect I the a/b MDS of our of AML higher-risk portion first Meeting.

also plan ASH. high-risk present event frontline the expansion year the initial mutant XXX following dose frontline combining from We AML company-sponsored data this TPXX azacitidine a fourth quarter cohort and MDS in to of the dose with cohort during expansion

program frontline milestones, in cohort fourth the in complete MDS enrollment the XXXX. quarter clinical of expect For to we higher-risk

PROC in combination our XXX to Ib this cohort the with enrollment fourth in plan Phase quarter of complete also dose We and of of PLD year. expansion

solid both results higher-risk MDS. significant studies potential of with Should These PROC in registration-directed CDXX AML first-to-market at studies. accelerated medical subsequent initial the and XXX hold of as agents and the maturity for are areas as our among need all in size have tumor development would and as well multiple heme opportunities the gathered unmet increase.

team, the protein believe I science milestones well experienced puts and position together, our into next our move beyond as resources engineering Taken as transformational XXXX. a combination financial strong us in of of set

many would we happy our people our who that, to questions. their call, patients are supportive the once Operator? have to team, today's been and entire like the way. With thank Shattuck the along and take investors I families, conclude we again Before

Operator

[Operator Instructions] line from the Jonathan Your ISI. Miller comes of of first question Evercore .

Jonathan Miller

granularity real these the detail bit on clinical Obviously, characteristics love are some these on on can start congrats more about you have platinum-resistant, patients. little POC to getting but therapy? a agents study little in and a give variety I'd to the here. baseline prior other of their more ask patients lines seen data of these And what bit of

maybe bit then open-ended. And little a more

patients gathering the aside which impact on the your these of seeing? programs, you're demonstrate able about to well have not are As molecule CDXX that responding, CDXX they other comping is for program did, that excitement the in to we what obviously think this been of the that have being efficacy expectation once ligand

Taylor Schreiber

why compare to I'll thanks question follow John's around Great. ahead don't answer part. the first the patients these and for the characteristics how questions. they baseline go of Lini, JAVELIN? with you you and then second And and

Arundathy Pandite

the resistant well Thank the you, John, to enrolled the these patients, for Yes, XX% these are patients patients The frontline study. the in to JAVELIN platinum. regimen platinum-containing compare question. frontline majority had very these patients of and were failed who and that's of

received patients PARP number So platinum. XX% . these bevacizumab. isn't patients of XXX% PARP but the had well deck, received also of received patients in slide also These as that had inhibitors, have these have patients received

Taylor Schreiber

how in needs XXX MDS patients and and XXX CDXX regard that compares the Great. other -- these evolved AML to Thanks, space in higher-risk how inhibitors. And . to show Lini. to with with what's

probably early for As on space have last purely that has an in would the under over be first reasons to AML the certain agents been the therefore, competitive X and of market, opportunity discontinued MDS most magrolimab the audience commercial been assumption the dwindled. space might this knows might have and higher-risk and years. evolving

data dose changed. had of ENHANCE we sharing their a that in around however, way earlier to forward these transparency. Gilead more as top as certainly It increase of more commitment have learn what impacted And enrolled line study. discontinued seems, to have that arms may Clearly, with And may happened of could readouts have that's hopefully, interruptions patients many and new that. the to we'll or though magrolimab look ENHANCE-X part the about exactly

alone, safety Regardless, models, syndication. of [indiscernible] response the patients destructive preclinical stand its improved durability. encouraged to of lack anemia. rates X translated improved and in profile, And feet the in clearly, differentiated And clearly, the has on we're both CDXX in agonism this, and by response then benchmarks to activity like own only just seeing improved like exceed rates, have but improved azacitidine over those overall with not rates, important CR over if survival. exceed. And do are to of of response magrolimab improved an and an drugs and if you CR expectations the AZA you duration Plus of prior opportunity

and XX% share from to MDS ASH to we'll Aprea what of the to exceed of the glimpse looking benchmark in in And response, at that be of higher-risk least double. And looking in population, azacitidine the see. so first certainly proximity about that's in complete by we're December. terms comes which study

And substantial CR in of delivers rates of we'll data, the digits to complete where and mutant by a and soon, alone I low TPXX the in hope the in seems AZA-Magro. combination look single but more terms response we'll the deliver rates cohort margin. azacitidine to low AML again, that exceed XXs get

more that have about So discontinued. hopefully learns that these as own on other show the been have field are the to things our we agents

Operator

Joe Pantginis H.C. comes of the next of Wainwright. question Your line from

Joseph Pantginis

the as see to well. data. Congrats Nice early

Taylor, maybe, or What more for MDS see analysis we to if or approval, focused wanted to TPXX out. cohorts do say, the say, expansion could do -- the maybe scenario envision obviously, So start some get I need targeting AML you with mutation? other initial read path targeted study. But you a could

regard of MDS in with response see to color you're any the study? starting to that provide you can AML also, then And the kinetics the

Taylor Schreiber

is high were an you be to frontline is the opportunity first in so. specific to expansion the there. certainly unmet a of know, If excess accelerated of there patients XX% setting, CR And there path hit rate TPXX medical for the as AML where in we or mutant an So very would one cohorts need. already even

duration be what benchmark. I we'll think exceed could that the X-month a response. that of as to would range in translate interesting be of something a into and indicator good where be terms in looking X-, of

study come would we expansion potential be mutant that in readouts agree opportunity. having and the confirm there that I that that next discussion incremental for the accelerated TPXX basis first path are be but about during of the And to third data. AML cohort subsequently, that enrolled to half do of what a fully And could regulators first, those expect there, registration-directed with year, the an is quarter.

of a the that patient response, relapsed/refractory terms can ASH In in on first the comment couple soon. of I -- we the disclosed kinetics certainly is data points the add that of abstract as of responder, came to and all, study response patient. -- we'll Lini of And this and AML have, tough they the [indiscernible] monotherapy. first . a on a cycle plus X XXX X, they monotherapy within they failed outlined, They've had then FLAG, this as failed failed a the was The

That's XXX response observed kinetics of a preclinical unusual with consistent for in like it's but models. this, that with we the the had patient of equivalent various

that response the that also say responders criteria. in met X at unconfirmed PROC PR could X-week also in case I the that's first started very PROC the they with And confirmed first scan. at the scan, that responder that X-week were

it how kinetics sets of at So trying data that to response when looking XXX translate. and helpful, initial the are appears might especially rapid that forecast to and that's

Operator

question next TD Marc from line of comes of Frahm Cowen. the Your

Marc Frahm

from scan X how many with, data the versus the who've first on Maybe discontinuing other off awaiting reasons? drug congrats start explain trial XX maybe for you today. having to still on the early just of Lini, in And the are seen response can those gap XX, the

the efficacy half of experience patients it's seeing those have that than PARP is any numbers, then of I maybe know in any . -- one are you the populations had not, if other? And small half more point the in the to sense about but

Taylor Schreiber

take those. question. thanks don't and Great. you go the why for ahead Lini, Mark,

Arundathy Pandite

connection. I the repeat first Sorry, question? . the you Mark, lost can

Marc Frahm

Yes. database safety are of explain are versus XX Sorry evaluable, of them just waiting in X can maybe other gap patient How there? reasons? the efficacy and first patients it has . The many you kind scan their today. XX discontinued the for for

Arundathy Pandite

All for on They are first are study. still scan. waiting X their

Marc Frahm

you're of patients? seeing, responses versus efficacy the type less And any Okay. maybe the non-PARP then experience in that sense or eligible of PARP this more is

Arundathy Pandite

it At is kind of to the conclusions. draw Mark, moment, early those too

first inhibitors. The first the received with PARP, received had had PARP the PR patient patient

. The second have the patients received patient -- -- X second next [indiscernible]

any draw So conclusions it's time. . at this to hard

Marc Frahm

MIRV sense. data. Makes folate see different when levels. couple based [ thinking level Okay. the expression initial -- we'll a MIRV of sorry, There's populations next And combo to year then forward on ] expression

can kind be robustness how be you'll you of able to Just you're . big frame expression able look across data expecting the provide of to the levels? different and those set to

Arundathy Pandite

we and to we low. be XX interesting are . subgroups. response include and expecting XX high, will ImmunoGen response those medium each of enroll working patients durability Yes, with up benchmark to are rate what in And to of That would patients. an

Operator

question BTIG. from line next Kaveri comes Your of . the of Pohlman

Unknown Analyst

Christian I'm Kaveri. on

close you I prior It at that guys answered patients was [indiscernible] of medium a know But receive about RR, required considering guys question. the So expressors. like bevacizumab. a you my combo and beyond you would . to receptor noticed meaningful that, just term registration trial, the Consider to folate being alpha actually what to trial of enrolling is this that low XXX% part are like

that a forward, make So this to plans trial? requirement also going there in are

Taylor Schreiber

as take Christian, for question don't that . you question. ahead well. Lini, and Great. the go thanks why

Arundathy Pandite

Thank the question. for you

. the exact SORAYA eligibility was ] criteria, So designed trial with [ the

So written. and that's the to received all how trial patients was . were bevacizumab have required

Unknown Analyst

are in planning take just the use to differences analysis use If you is question next guys PLD this [indiscernible] are my future? other trial, the and And it. planning in you . biomarker responders nonresponders? patients to so, to determine to Got

Taylor Schreiber

Yes. Christian. Thanks,

of to from continuing ASCO earlier and pre- cells. similar the variety in patients. We of cytokine cells is peripheral some to data from data was the as immunophenotype changes expressing responses, both regard year a these of with of are through these evaluation different peripheral collect this on-treatment which margination as patients CDXX biomarker our that of well in shared to biopsies abstract

the certainly that we'll at that, may the size report set subsequent a the inform selection increases data study. of or patient strategy hope toward analysis And as responder, data . nonresponder of we date. But a the on a end that

Operator

from [Operator line Instructions] the Yigal question Citi. comes your of of Nochomovitz next

Yigal Nochomovitz

the I respect these any if between effective to XXX biologic you higher-risk and at On or wondering looked to potentially degree MDS, you would patients any PROC, the response? And have with in TPXX one plan . in interval versus already at just look was combo for reason of be you or the the hypothesis have on then platinum-free cohorts if of correlation believe frontline and these more that do studies to the other? heme

Taylor Schreiber

Sure.

XX% progressed mentioned, date the within Lini to of platinum. months X the study first the As of enrolled patients in PROC

homogeneous alluded to distinguish that if is within And so try it platinum group we set size can the between can the enough these All poor kinetics really fairly were disease. is rapidly a all progressed a prognosis before, primary And say to X of did Lini platinum on where we rapid X make months. this to resistant to of difference large X to -- we data with is not versus as the patients of X that patient

mutant diseases. a in with azacitidine what mutant to can soon difference wild-type say prior is versus AML AML we're because otherwise, higher-risk And TPXX I are with to TPXX with more than patients data mystery patients bit sharing there's whether there that it's do why And looking better quite always cohorts. similar regard a of little the the seem been subpopulations a frontline TPXX bit or the in to with studies a conjunction forward those then some MDS the

out TPXX T were perhaps hypotheses is of the was framed that a to agonist the CDX+ in literature inhibitor be And mutant one tumor-infiltrating that tumor of immunogenic burden. characteristics was some patients. more Perhaps more value a i.e., to the of the normalized those have part seem of adding cells, a of patients And mutational it there start. that's there the immune-activating the than of been higher might because around a wild-type some potential CDXX of the XX. expectation TPXX CDXX proposition to

we're looking X be data And months. say case, and the sharing that it's soon next so a at. the necessarily certainly something that, that would indeed but over we following priority, to we'll And can't be X that

Operator

the comes Gil Blum of question Needham next Your Company. line of & from .

Gil Blum

So maybe PROC? -- to ovarian go/no-go you just you PLD here. on relevant faced focus here would mean and a the on decision plus as And gauge these cancer. PLD XXX? I days how What is some enrollment challenges

I'd follow-up. So your And X here. love sense . have I a

Taylor Schreiber

doesn't took And now long study. us when the the this for mean very study enrollment question. I because this the it's -- is of as thanks that the enroll Yes, first it much as complete Elior the joined -- first as in X I there -- complete study, highlighted help can patients has these arm many the investigators JAVELIN in PLD study, because about in you to the tell who to study patients. by now it we started were only

what And perceptions something then synergy, in this away that's I and heme if yet. And the and data people setting. solids. always from can starting to the mean right? we data, be PLD see XXX quite we're and seem say think can't will is -- hold, in adding that both to And shy that word certainly, these changed But by

if an meaningful PROC could months. very non-biomarker in meaningful a itself and all-comer that is of be be in This an by duration and setting, of response rate all-comer it excess selected XX% is X a exceeds could population and of response accompanied in

be And the half so of benchmarks over those mature -- that we as looking next first towards as year. will are the we data

XX and patients a study. or discussion the basis registration-direct be patients with terms the next results momentum, between first for of current of that be. incremental and to on of to mutant study enroll be so. my And step similar would the to regulatory cohort our that would current in an TPXX comments we'd confirm adding expansion XX the at the what looking AML and those the somewhere

Gil Blum

nonresponding stable see Excellent. a can you you immuno-oncology, diseases diseases. of long of? Very per helpful. a And In of stable my is, of the in times . the lot sense get behavior kind follow-on patients lease

Taylor Schreiber

too Sure. It's early much. say to too

and think a varying As to, I of were the Lini X from initial data XX-patient of of the they disease this. we the you disease progressive had lengths of for full expect about balance X best and best any population with cohort make a we whether disease response of had need had to a assertions response longer time. patients those set of before alluded can than stable patients out X stable like disease And in patient wait see stable would

Operator

Executive Thank you. the to the Chief of Taylor At This Shattuck concludes Q&A this for Officer back like remarks. would I call. time, to Schreiber, call over session of Labs the turn closing .

Taylor Schreiber

Update we continued look Conference Shattuck Shattuck Labs' Financial XXXX Business appreciate your you. later Thank interest Call. and Results you, to Thank you updating operator, on joining forward We Third and thank year. for this milestones and the Quarter you all our in

Operator

you for conference participating. today's Thank concludes This call.

disconnect. now Have may You a day. wonderful

Shattuck Labs (STTK) 9 Nov 232023 Q3 Earnings call transcript